Annals of medicine and surgery (2012) · 2026
A narrative review on the neurobiology of lucid dreaming: mechanisms and therapeutic potential.
Источник пометил эту публикацию как отозванную.
СтатьяОбзорОтозванная публикацияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Tirath, Ahmad Ashfaq, Irshad Kinza, Ullah Rahat, Noor Anaya, Anwar Eiman, Khan Rai Muhammad Umar, Akhtar Moazzam, Henna Fathimathul, Iltaf Arej, Filal Maryem, Fatima Syeda Kashaf, Hanani Christopher, Anand Nikhilesh
Аннотация
BACKGROUND: Lucid dreaming (LD), which involves being aware of and controlling one's dreams, is of particular interest in the study of consciousness and has potential therapeutic applications. In this narrative review, we highlight the neurobiological aspects of LD, specifically its mechanisms associated with the activation of prefrontal and parietal areas, increased gamma oscillations, and the influence of cholinergic and dopaminergic signaling, primarily during rapid eye movement (REM) sleep.
OBJECTIVE: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams.
METHODS: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson's] and healthy individuals (18-45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated.
RESULTS: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns.
CONCLUSION: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.
OBJECTIVE: To evaluate human data on brain mechanisms and clinical effects, synthesizing the neurobiological foundations and therapeutic possibilities of LD, including remarkably controlled lucid dreams.
METHODS: A narrative review of peer-reviewed research involving clinical groups [e.g., post-traumatic stress disorder (PTSD), chronic nightmares, Parkinson's] and healthy individuals (18-45) was synthesized. Objective lucidity verification [vented eye movements, electroencephalography (EEG)/functional magnetic resonance imaging] was a requirement for inclusion criteria. Neurobiological indicators (gamma, alpha, beta waves, and prefrontal cortex/parietal activation), therapeutic benefits (e.g., frequency of nightmares, PTSD and anxiety scores, motor and cognitive gains), and safety and ethical considerations (dissociation and sleep disruption) were among the outcomes evaluated.
RESULTS: LD demonstrates efficacy in modulating nightmares, improving cognitive functions, and potentially alleviating some symptoms in PTSD and neurodegenerative disorders, albeit with methodological constraints. Developments in portable EEG and virtual reality headsets will refine LD research, while interdisciplinary approaches are necessary to address potential risks of dissociation and privacy concerns.
CONCLUSION: Although evidence remains preliminary, LD shows promise as a therapeutic remedy for PTSD and anxiety symptoms, including a reduction in nightmares. It combines neuroscience and self-agency, highlighting the need for more funding and public awareness campaigns to harness its scientific and clinical prospects. Larger randomized trials with a variety of groups and standardized induction techniques are necessary to verify long-term efficacy and safety.